Effects of liposomal paclitaxel and paclitaxel in treatment of non-small-cell lung cancer(64 patients) and breast cancer(62 patients)

AIM: To analyze the efficacy and safety of liposomal paclitaxel in comparison with paclitaxel for patients with non-small-cell lung cancer and breast cancer. METHODS: Sixty-four patients with non-small-cell lung cancer were randomized to be treated with liposomal paclitaxel plus cisplatin or paclitaxel plus cis-platin. Sixty-two patients with breast cancer were randomized to be undertaken liposomal paclitaxel plus epiru-bicin or paclitaxel plus epirubicin therapy, response was evaluated after 2 courses of chemotherapy.The patients therapeutic course was discontinued when disease progressed. RESULTS: Of 126 patients,there were 120 eligible for the analysis of overall response rate and 126 for adverse reactions.Overall response rates of patients with non-small-cell lung cancer was 27 % for liposomal paclitaxel plus cisplatin group and 17 % for paclitaxel plus cisplatin group (P 0.05). Overall response rate of patients with breast cancer was 43 % for liposomal paclitaxel plus epirubicin group and 37 % for paclitaxel plus epirubicin group (P 0.05). There was no significant difference in serious adverse reactions between the two groups.There were three patients (5 %) treated with paclitaxel showed grade Ⅲ allergic reaction outcoming with discontinuation of the treatment. CONCLUSION: Liposomal paclitaxel is effective and safe for the treatment of non-small—cell lung cancer and breast cancer.